Efficacy and safety of litifilimab in cutaneous lupus erythematosus: 24-week results of the randomized phase 2 study, AMETHYST.
BACKGROUND Cutaneous lupus erythematosus (CLE) is a serious autoimmune disease with no approved targeted treatments. OBJECTIVE Evaluate the efficacy and safety of litifilimab in AMETHYST Part A (Phase 2). METHODS AMETHYST is a randomized, double-blind, placebo-controlled, Phase 2/3 study that investigates litifilim...